World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
117
Citations
54210
World Ranking
4192
National Ranking
408

Philip J. Johnson publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Philip J. Johnson sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 530 publications — 63rd percentile

63% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Philip J. Johnson D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Philip J. Johnson sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 117 D-Index — 80th percentile

80% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Philip J. Johnson is affiliated with the University of Liverpool in the United Kingdom and has an extensive publication record focused primarily on medicine, with a significant emphasis on hepatology. Their research spans various subfields including hepatology, epidemiology, cancer research, oncology, and surgery.

Johnson's main topics of work include:

  • Liver Disease Diagnosis and Treatment
  • Hepatocellular Carcinoma Treatment and Prognosis
  • Hepatitis C Virus Research
  • Liver Disease and Transplantation
  • Cancer, Lipids, and Metabolism
  • Hepatitis B Virus Studies
  • Pancreatic and Hepatic Oncology Research

Their frequent coauthors are:

  • Hidenori Toyoda
  • Sarah Berhane
  • Hamish Innes
  • Takashi Kumada
  • Alessandro Cucchetti

Johnson has published multiple papers in prominent venues. The frequent publication venues include:

  • Journal of Hepatology
  • British Journal of Cancer
  • JHEP Reports
  • Liver Cancer
  • Clinical Gastroenterology and Hepatology

Some of the recent papers featuring Philip J. Johnson as an author include:

  • Circulating biomarkers in the diagnosis and management of hepatocellular carcinoma, 2022, Nature Reviews Gastroenterology & Hepatology
  • aMAP risk score predicts hepatocellular carcinoma development in patients with chronic hepatitis, 2020, Journal of Hepatology
  • The ALBI score: From liver function in patients with HCC to a general measure of liver function, 2022, JHEP Reports
  • Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma, 2022, Liver Cancer
  • Locoregional therapies in patients with intrahepatic cholangiocarcinoma: A systematic review and pooled analysis, 2021, Cancer Treatment Reviews

The scientist's work concentrates especially on liver diseases, including hepatocellular carcinoma, and the development and evaluation of diagnostic biomarkers and treatment approaches. They have conducted research across epidemiological and clinical domains focusing on liver disease prognosis and therapy.

Best Publications

  • Quantitative Analysis of Fetal DNA in Maternal Plasma and Serum: Implications for Noninvasive Prenatal Diagnosis

    Y. M. Dennis Lo;Mark S.C. Tein;Tze K. Lau;Christopher J. Haines

  • Assessment of Liver Function in Patients With Hepatocellular Carcinoma: A New Evidence-Based Approach—The ALBI Grade

    Philip J. Johnson;Sarah Berhane;Chiaki Kagebayashi;Shinji Satomura

  • Meeting report: International autoimmune hepatitis group

    P. J. Johnson;Ian G. McFarlane

  • Efavirenz plus Zidovudine and Lamivudine, Efavirenz plus Indinavir, and Indinavir plus Zidovudine and Lamivudine in the Treatment of HIV-1 Infection in Adults

    Schlomo Staszewski;Javier Morales-Ramirez;Karen T. Tashima;Anita Rachlis

  • Global patterns of hepatocellular carcinoma management from diagnosis to death: The BRIDGE Study

    Joong Won Park;Minshan Chen;Massimo Colombo;Lewis Rowland Roberts

  • Quantitative Analysis of Cell-free Epstein-Barr Virus DNA in Plasma of Patients with Nasopharyngeal Carcinoma

    Y. M.Dennis Lo;Lisa Y.S. Chan;Kwok Wai Lo;Sing Fai Leung

  • Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors

    Winnie Yeo;Paul K.S. Chan;Sheng Zhong;Wing M. Ho

  • Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

    Philip J. Johnson;Shukui Qin;Joong Won Park;Ronnie T.P. Poon

  • A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma.

    Winnie Yeo;Tony S. Mok;Benny Zee;Thomas W. T. Leung

  • Detection of Aberrant p16 Methylation in the Plasma and Serum of Liver Cancer Patients

    Ivy H.N. Wong;Y. M.Dennis Lo;Jun Zhang;Choong Tsek Liew

  • Overall Survival After Concurrent Cisplatin-Radiotherapy Compared With Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma

    Anthony Tak-cheung Chan;Sing-fai Leung;Roger K.C. Ngan;Peter M.L. Teo

  • Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy†

    Winnie Yeo;Philip J. Johnson

  • Concurrent Chemotherapy-Radiotherapy Compared With Radiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma: Progression-Free Survival Analysis of a Phase III Randomized Trial

    A.T.C. Chan;P.M.L. Teo;R.K. Ngan;T.W. Leung

  • Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result?

    I. G. McFarlane;H. M. Smith;P. J. Johnson;G. P. Bray

  • Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.

    Masatoshi Kudo;Kazuomi Ueshima;Masafumi Ikeda;Takuji Torimura

  • Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial.

    Ghassan K. Abou-Alfa;Philip Johnson;Jennifer J. Knox;Marinela Capanu

  • Quantitative and Temporal Correlation between Circulating Cell-Free Epstein-Barr Virus DNA and Tumor Recurrence in Nasopharyngeal Carcinoma

    Y. M. D. Lo;L. Y. S. Chan;A. T. C. Chan;S.-F. Leung

  • Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial.

    Tim Meyer;Tim Meyer;Richard Fox;Yuk Ting Ma;Paul J Ross;Paul J Ross

  • The Role of Serum Alpha-Fetoprotein estimation in the Diagnosis and Management of Hepatocellular Carcinoma

    Philip J. Johnson

  • Plasma Epstein-Barr Virus DNA and Residual Disease After Radiotherapy for Undifferentiated Nasopharyngeal Carcinoma

    Anthony T C Chan;Y. M Dennis Lo;Benny Zee;Lisa Y S Chan

Frequent Co-Authors

Winnie Yeo
Winnie Yeo Chinese University of Hong Kong
Anthony T.C. Chan
Anthony T.C. Chan Chinese University of Hong Kong
Paul B.S. Lai
Paul B.S. Lai Chinese University of Hong Kong
Tony Mok
Tony Mok Chinese University of Hong Kong
Y.M. Dennis Lo
Y.M. Dennis Lo Chinese University of Hong Kong
Roger Williams
Roger Williams Foundation for Liver Research
Ka-Fai To
Ka-Fai To Chinese University of Hong Kong
Hidenori Toyoda
Hidenori Toyoda Ogaki Municipal Hospital
Stephen L. Chan
Stephen L. Chan Chinese University of Hong Kong
Benny Chung-ying Zee
Benny Chung-ying Zee Chinese University of Hong Kong

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students considering a career in medicine, there are diverse online degree options that can help shape your journey. Many are searching for ways to fast-track their healthcare education, and several accredited programs now offer this flexibility.

For those aiming at advanced nursing roles, the shortest dnp programs online allow you to earn a Doctor of Nursing Practice in less time. Budget-minded students may wish to explore a cheapest dnp program, which provides high-quality education with lower tuition costs.

If you’re interested in starting your healthcare career quickly, a 6 month lpn program online could offer the fastest route to practical nursing. For those drawn to mental health, the fastest pmhnp program enables registered nurses to specialize as psychiatric mental health nurse practitioners in less time than traditional paths.

Whether your goal is to advance into specialized practice or quickly enter the nursing workforce, these flexible online pathways offer practical solutions for aspiring healthcare professionals.

Best Scientists Citing Philip J. Johnson

Trending Scientists

Recently Published Articles